The Effect Of Lisinopril On Polycythemia
ConditionPolycythemia
Trial statusNot yet recruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexAll
Age18-80
SponsorMayo Clinic
About this trial
The purpose of this study is to evaluate the effect of the (angiotensin-converting enzyme) ACE inhibitor lisinopril on hemoglobin, hematocrit, and erythropoietin levels in patients with secondary polycythemia due to high-oxygen-affinity hemoglobin variants, oxygen-sensing pathway mutations, or other unexplained and potentially irreversible forms of erythrocytosis. This study aims to determine whether ACE inhibition can effectively reduce excessive erythrocytosis by modulating erythropoietin production.
Eligibility criteria
Qualifiers
Hemoglobin in Men: >16.5 g/dL (10.3 mmol/L).
Hemoglobin in Women >16.0 g/dL (10.0 mmol/L).
BMI 18-40 kg/m2.
Disqualifiers
Positive JAK2 gene linked to Polycythemia Vera.
Current smoker or previous heavy smoker (>15 pack years) who quit less than 12 months prior to enrollment.
Resting SpO₂ ≤ 94% on room air.
Current or recent (within the past 6 months) use of testosterone or androgen supplementation.
Trial design
Treatments tested in this trial
- Lisinopril Tablets
Treatment groups
30 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov